116052-94-9

Upstream product

• 4129-17-3 diphenylphosphoranyl azide 

Downstream Products

• 873784-00-0 trimethyl (4R,7R,10R)-α,α',α''-tetramethyl[(S)-2-(nitrobenzyl)]-1,4,7,10-tetraazacyclododecane-4,7,10-triacetate 
• 873783-99-4 trimethyl (4S,7S,10S)-α,α',α''-tetramethyl[(S)-2-(nitrobenzyl)]-1,4,7,10-tetraazacyclododecane-4,7,10-triacetate 
• 873784-02-2 tetramethyl (4R,7R,10R)-α,α',α''-trimethyl[(S)-2-(nitrobenzyl)]-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate 
• 873784-01-1 tetramethyl (4S,7S,10S)-α,α',α''-trimethyl[(S)-2-(nitrobenzyl)]-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate 
• 1072159-82-0 C₄₃H₈₁N₉O₁₈P₄ 
• 1224513-61-4 2-(S)-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid tetrabenzyl ester 
• 1277182-09-8 2-p-nitrobenzyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(methylcarbonylamide) 
• 1335131-17-3 C₄₃H₆₉N₉O₁₄ 
• 1335131-18-4 C₆₃H₇₇N₉O₁₄ 

Relevant academic research and scientific papers

Synthesis, in vitro progesterone receptors affinity of gadolinium containing mifepristone conjugates and estimation of binding sites in human breast cancer cells

Novel gadolinium-based mifepristone conjugates were synthesised using various synthetic routes. Moderate antiprogestagenic activity of the new conjugates was observed in human breast cancer cells (T47-D cells) using AP (alkaline phosphatase) assay. The amount of incorporated Gd determined by inductively coupled plasma mass spectroscopy (ICPMS) indicates the number of binding sites per cell. These conjugates might be important compounds to develop receptor-targeted MRI contrast agents as well as other anti-breast cancer therapeutics.

Pretargeting methods and compounds

Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Articles of manufactur

Pretargeting methods and compounds

Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Articles of manufacture useful in pretargeting methods are also discussed.